Related Experiment Video
Updated: May 20, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Companion diagnostics: emerging strategies and issues in pharmaceutical development
Janette Thomas1, Elyse Stratton, Mieke Keppens
1Integrated Medicines Ltd, Director of Programmes, Topfield House, Ermine Street, Caxton, Cambridge, CB23 3PQ, UK. janette.thomas@integratedmedicines.co.uk
Abstract:
This article summarizes the broad messages from pharmaceutical and diagnostic companies on the collaborations required to support companion diagnostics. Since the groundbreaking herceptin HER2 diagnostic model in 1998, it has taken until 2011 for the US FDA to issue a draft guidance document, which was then immediately followed with approvals for two new drugs and their companion diagnostics. This conference summarized the current state of thinking in new projects and innovative technologies in pharmaceutical and diagnostic codevelopment. Attitudes are slowly changing and collaborations are rapidly ensuing, although the alignment between pharmaceutical and diagnostic understanding of value, timelines, outcomes and impact is difficult and remains a contentious area. The value of this conference has been to address these issues.
Related Concept Videos
Preclinical Development: Overview
Drug Discovery: Overview
Clinical Trials: Overview
Therapeutic Drug Monitoring: Drug Analysis Methods
Pharmacogenomics: Identification of New Drug Targets
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

